Evidence map›Paper›PMID 29968144›Full record

ArticleInternational urology and nephrology2018

Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder.

Murat Uçar, Ahsen Karagözlü Akgül, Ayşe Parlak, Cem Yücel, Nizamettin Kılıç, Emin Balkan

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Murat UçarSection of Pediatric Urology, Department of Urology, Health Sciences University, Tepecik Education and Research Hospital, 35180, İzmir, Turkey. drmuratucar@hotmail.com.ORCID http://orcid.org/0000-0001-6977-7430
Ahsen Karagözlü AkgülSection of Pediatric Urology, Department of Pediatric Surgery, Health Sciences University, Van Education and Research Hospital, Van, Turkey.
Ayşe ParlakDepartment of Pediatric Surgery, Uludağ University Medical Faculty, 16059, Bursa, Turkey.
Cem YücelDepartment of Urology, Health Sciences University, Tepecik Education and Research Hospital, 35180, İzmir, Turkey.
Nizamettin KılıçDivision of Pediatric Urology, Department of Pediatric Surgery, Uludağ University Medical Faculty, 16059, Bursa, Turkey.
Emin BalkanDivision of Pediatric Urology, Department of Pediatric Surgery, Uludağ University Medical Faculty, 16059, Bursa, Turkey.
Bursa Uludağ Üni̇versi̇tesi̇ · TRIzmir University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to evaluate the efficacy and safety of intravesical onabotulinum toxin A (onaBoNTA) injections for the treatment of children diagnosed with refractory overactive bladder (OAB) by using non-invasive methods.

methodsA total of 31 pediatric patients with a mean age of 10.2 years received intravesical onaBoNTA injection at the dose of 10 U/kg (max: 200 U). Twenty-one patients who failed to respond to the first injection, received second injection 6 months after the first one. The patients were retrospectively evaluated after the 1st and the 2nd injections by means of standardized questionnaire forms and voiding diary records.

resultsIn the 6-month follow-up, 10 patients (32.2%) were determined to have full response after the first injection. The number of patients with partial response and no response were found to be 15 (48.4%) and 6 (19.4%), respectively. The mean value of Dysfunctional Voiding and Incontinence Symptom Score (DVISS) of the patients with full response was 8.5 before the injection, which decreased to 1 at 6-month follow-up and to 0.5 at 12-month follow-up (p < 0.001). Twenty-one patients without full response after the first injection received a second injection 6 months after the first one. Full response was achieved in 9 (42.9%) of the 21 patients who had a second injection, but only partial response was achieved in 9 (42.9%). Three (14.3%) of the remaining patients did not respond to the second injection either. 1-year follow-up evaluations revealed that the rates of the full response, partial response, and no response were 61.3, 29, and 9.7%, respectively.

conclusionsBased on our results, onaBoNTA therapy is an effective and reliable second-line off-label therapy in the management of patients with non-neurogenic OAB that is refractory to medical therapy. Asking the patients/guardians to fill out a standardized questionnaire form before and after the therapy enables easy and non-invasive assessment of the response to the therapy.

Indexed as

Administration, IntravesicalAdolescentBotulinum Toxins, Type AChildDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansMaleNeuromuscular AgentsRetrospective StudiesTime FactorsTreatment OutcomeUrinary Bladder, OveractiveUrinationBotulinum Toxins, Type ANeuromuscular AgentsBotulinum toxin AChildrenOveractive bladderUrgencyUrinary incontinence

Identifiers

PMID29968144
OpenAlexW2810534523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.